Verapamil in the long-term treatment of angina pectoris.
1. A long-term, open clinical trial of verapamil therapy was conducted in ninety-three patients with coronary artery disease, selected on the basis of having stable angina pectoris and of being unsuitable for treatment with beta-adrenoceptor blocking drugs. 2. Two-thirds of the patients (fifty-eight patients) obtained a good relief which was sustained over a period of 1 y. There were few major adverse reactions and the drug was generally well tolerated. The main limiting factor in dosage was hypotension. No adverse effects were observed in patients with obstructive airways disease, controlled cardiac failure and lower limb arteriosclerosis. 3. Verapamil was considered to be a major advance in the chronic therapy of angina pectoris.
D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy*; D001919:Bradycardia / Q000139:chemically induced; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003248:Constipation / Q000139:chemically induced; D003327:Coronary Disease / Q000150:complications / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D005260:Female; D006261:Headache / Q000139:chemically induced; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D014700:Verapamil